The Next Life-Changing Cannabinoid Success story has gone mainstream and one biopharma is set to dominate

Is Marijuana the next Antibiotic? As early as 10 years ago, it was discovered that Cannabinoids harvested from cannabis plants could possibly surpass conventional antibiotics in the escalating war against drug-resistant bacteria. Cannabinoids appear to be unaffected by the mechanism that superbugs like MRSA use to evade existing antibiotics.

Cannabis has long been known to have antibacterial properties and was studied in the 1950s as a treatment for tuberculosis and other diseases. But research into using cannabis as an antibiotic has been limited by poor knowledge of the plant’s active ingredients and by the controversy surrounding its use as a recreational drug.

This headline came across my monitor and I nearly jumped. The trends are changing in the Alternative Medicine Industry and cutting edge companies such as VBIO are quickly becoming the trendsetter.

The problem is not the drugs themselves; it’s the bacteria which makes us sick.

How many of you had a flu shot this past winter? Ever wonder why we need to get injected every year?

Antibiotic Resistance: A Huge Problem Antibiotics must be updated constantly in order to keep up with rapidly changing bacteria that make us sick. Bacteria evolve quickly and rising antibiotic-resistant strains can cause major problems for humans. Medical Professionals feel the increasing resistance against antibiotics is fueled by over-prescription of these drugs for ailments for which they are not necessary. This creates opportunity for bacteria to evolve, and create pathways to counter the antibiotics.

Today, there are five major reasons why we continue to lose the battle against bacterium and microbes:

Over prescription of antibiotics by doctors

Overuse of antibiotics in animal agriculture

Improper consumption of antibiotics by patients

Overuse of household products that contain antibiotics

Overuse of cosmetics and toiletries that contain antibiotics

Cannabis has been found to have impressive anti-microbial qualities and the ability to fight many bacterial infections that can no longer be properly combatted by antibiotics.

If you’re looking for the next big marijuana story, this has to be it. Let’s take a deeper look into this prodigious announcement.

Vitality Biopharma, Inc. (OTCQB: VBIO) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has obtained positive results demonstrating antimicrobial activity of cannabinoids and filed for patent protection on the use of cannabinoid compounds for the treatment of microbes including Clostridium difficile and other “superbug” pathogens.

After examining the top drug-resistant pathogens from the United States Centers for Disease Control and Prevention (CDC), Vitality researchers screened for antimicrobial activity in their portfolio of compounds.

VBIO discovered new antimicrobial activities for cannabinoids, and as a result has filed for patent protection on the use of cannabinoids and cannabinoid prodrugs for the treatment of multiple pathogenic bacterial infections.

So if I am understanding this correctly, this one company, VBIO – might hold the keys to the future for health and medicine.

Life Changing???

Mind Blowing???

Medical Revolution???

Only two new class of antibiotics have been introduced in the past 30 years. This fact is quite scary, especially considering that we developed 20 new classes between 1940 and 1962. Bacteria and microbes evolve at a much faster rate than we’re able to intelligently prevent them. As far as antibiotics go, it’s us versus nature and nature is winning.

You may be asking how this is even possible and how come we’re just now learning about it.

To the marijuana plant, cannabinoids function like an external immune system. They’re chemicals that help protect the plant from disease and other environmental factors that might harm them. So, it really makes quite a lot of sense that these compounds could be quite useful in killing bacteria in humans and animals as well.

At the top of the CDC’s list is Clostridium difficile (C. diff), which is classified as an urgent threat to human health. The CDC reported in 2015 that it infected almost 500,000 Americans and was directly responsible for 15,000 deaths. VBIO successfully demonstrated antimicrobial reactivity of a cannabinoid against C. diff, and is currently conducting follow-on studies designed to enable pharmaceutical use of their targeted cannabinoid prodrugs for this application.

“Our cannaboside prodrugs enable the targeted delivery of cannabinoids into the large intestine, where C.diff infections colonize, take over, and can cause severe damage. Our compounds are uniquely suited for performing this task, and it’s now clear they may provide benefits to gut health through multiple mechanisms.”~ Dr. Brandon Zipp, Director of R&D at Vitality.

Is Marijuana the Super Antibiotic of the Future? It’s not often investors have an opportunity to be on the forefront of a medical revolution….

In an industry experiencing unprecedented growth…

Properly positioned where government is encouraging research and development…

With a company containing a proven edge – possibly years ahead of their competitors…

Trading at a fraction of some of its’ competitors.

With a Killer Breakout Chart

This is one of those times.

Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. WallStreet420.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for by Cannabis Wheaton in an effort to enhance public awareness of Cannabis Wheaton and its securities. Winning Media has or expects to receive four hundred thousand dollars by Cannabis Wheaton Cannabis Wheaton as a total production budget for this advertising effort. Neither WallStreet420.com or Winning Media currently holds the securities of Cannabis Wheaton and does not currently intend to purchase such securities. This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cau se actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at www.sec.gov readers can review all public filings by the Company at the SEC’s EDGAR page. WallStreet420.com is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.